Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2024 financial results and recent portfolio execution. The event will be accessible through the Investors & Media section of the company's website. Interested participants can register for telephone access, and a replay will be available on the website within 48 hours after the event.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) ha annunciato che ospiterà una conference call e un webcast dal vivo il martedì 25 febbraio 2025 alle 8:30 ora orientale per riportare i suoi risultati finanziari del quarto trimestre e dell'anno intero 2024 e l'esecuzione recente del portafoglio. L'evento sarà accessibile tramite la sezione Investitori e Media del sito web dell'azienda. I partecipanti interessati possono registrarsi per l'accesso telefonico, e una registrazione sarà disponibile sul sito web entro 48 ore dopo l'evento.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) ha anunciado que llevará a cabo una conferencia telefónica y una transmisión en vivo el martes 25 de febrero de 2025 a las 8:30 a.m. hora del Este para informar sobre sus resultados financieros del cuarto trimestre y del año completo 2024 y la ejecución reciente de su cartera. El evento será accesible a través de la sección de Inversores y Medios en el sitio web de la empresa. Los participantes interesados pueden registrarse para acceder por teléfono, y una grabación estará disponible en el sitio web dentro de las 48 horas posteriores al evento.
키니크사 제약 (Nasdaq: KNSA)는 2025년 2월 25일 화요일 오전 8:30 동부 표준시(Eastern Time)에 2024년 4분기 및 연간 재무 결과와 최근 포트폴리오 실행에 대해 보고하기 위해 컨퍼런스 콜 및 라이브 웹캐스트를 개최한다고 발표했습니다. 이 이벤트는 회사 웹사이트의 투자자 및 미디어 섹션을 통해 접근할 수 있습니다. 관심 있는 참가자는 전화 접속을 위해 등록할 수 있으며, 이벤트 후 48시간 이내에 웹사이트에서 재생이 가능합니다.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) a annoncé qu'elle organisera une conférence téléphonique et un webinaire en direct le mardi 25 février 2025 à 8h30, heure de l'Est, pour présenter ses résultats financiers du quatrième trimestre et de l'année 2024 ainsi que l'exécution récente de son portefeuille. L'événement sera accessible via la section Investisseurs et Médias du site web de l'entreprise. Les participants intéressés peuvent s'inscrire pour un accès téléphonique, et un enregistrement sera disponible sur le site dans les 48 heures suivant l'événement.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) hat bekannt gegeben, dass am Dienstag, den 25. Februar 2025 um 8:30 Uhr Eastern Time eine Telefonkonferenz und ein Live-Webcast stattfinden werden, um über die Finanzergebnisse des vierten Quartals und des gesamten Jahres 2024 sowie über die jüngste Umsetzung des Portfolios zu berichten. Die Veranstaltung wird über den Bereich Investoren und Medien auf der Unternehmenswebsite zugänglich sein. Interessierte Teilnehmer können sich für den telefonischen Zugang registrieren, und eine Wiederholung wird innerhalb von 48 Stunden nach der Veranstaltung auf der Website verfügbar sein.
- None.
- None.
LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2024 financial results and recent portfolio execution.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio assets are based on strong biologic rationale or validated mechanisms and offer the potential for differentiation. For more information, please visit www.kiniksa.com.
Every Second Counts! ®
Kiniksa Investor Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com
Kiniksa Media Contact
Tyler Gagnon
(781) 431-9100
tgagnon@kiniksa.com
FAQ
When will Kiniksa Pharmaceuticals (KNSA) report Q4 and full-year 2024 earnings?
How can investors access KNSA's Q4 2024 earnings call?
Will KNSA's Q4 2024 earnings call be available for replay?
What topics will be covered in KNSA's Q4 2024 earnings call?
